- Home | Harrow, Inc.
Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability
- Careers | Harrow, Inc.
At Harrow, we’re always interested in connecting with talented, purpose-driven, and mission-minded individuals who share our passion for advancing eye health and improving patients’ lives
- Products | Harrow, Inc.
Harrow has contracted for the U S commercial rights to BYQLOVI™, BYOOVIZ®, and OPUVIZ™ These products will be added to this section once they are launched by Harrow
- Corporate Presentation November 2025 - harrow. com
Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
- Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Integration into Harrow: Melt Pharmaceuticals will be fully integrated into Harrow’s operations to ensure a seamless transition and accelerate progress toward NDA submission, approval, and market launch
- Investor Relations | Harrow, Inc.
Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
- Harrow To Report Third Quarter 2025 Financial Results After Market . . .
The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow com Harrow will host a conference call and live webcast at 8:00 a m Eastern Time on Tuesday, November 11, 2025, to discuss the results and provide a business update
- Form 8-K for Harrow INC filed 10 06 2025
Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes For more information about Harrow, please visit harrow com
|